Mosaic Mitral Valve: Long-Term Outcomes in Patients Under 65
Long Term Patient Outcomes and Product Durability of the Mosaic Mitral Valve Bioprosthesis in Patients Under 65
Michael Moront
300 participants
Jan 1, 2025
OBSERVATIONAL
Conditions
Summary
The safety and efficacy of the Mosaic bioprosthetic heart valves for cardiac valve replacement in the aortic position has been well documented throughout the literature. However, few studies assessing structural valve deficiency, patient outcomes and overall product performance in patients under the age of 65 exists for the Mosaic mitral valve bioprosthetic. This study aims to assess valve efficacy, stability, and post operative outcomes in patients who have received the Mosaic mitral valve prothesis at ProMedica Toledo Hospital and were under the age of 65.
Eligibility
Inclusion Criteria2
- Received the Mosaic Mitral Valve Bioprosthetic at ProMedica Toledo Hospital
- Under the age of 65
Exclusion Criteria3
- Over the age of 65
- Under the age of 18
- Surgery performed at institutions outside of ProMedica Toledo Hospital
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06917586